Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1681/ASN.2021091257

http://scihub22266oqcxt.onion/10.1681/ASN.2021091257
suck pdf from google scholar
34907031!8819985!34907031
unlimited free pdf from europmc34907031    free
PDF from PMC    free
html from PMC    free
PDF vom PMID34907031  :  Publisher

suck abstract from ncbi

pmid34907031
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Secondary Immunodeficiency Related to Kidney Disease (SIDKD)-Definition, Unmet Need, and Mechanisms #MMPMID34907031
  • Steiger S; Rossaint J; Zarbock A; Anders HJ
  • J Am Soc Nephrol 2022[Feb]; 33 (2): 259-278 PMID34907031show ga
  • Kidney disease is a known risk factor for poor outcomes of COVID-19 and many other serious infections. Conversely, infection is the second most common cause of death in patients with kidney disease. However, little is known about the underlying secondary immunodeficiency related to kidney disease (SIDKD). In contrast to cardiovascular disease related to kidney disease, which has triggered countless epidemiologic, clinical, and experimental research activities or interventional trials, investments in tracing, understanding, and therapeutically targeting SIDKD have been sparse. As a call for more awareness of SIDKD as an imminent unmet medical need that requires rigorous research activities at all levels, we review the epidemiology of SIDKD and the numerous aspects of the abnormal immunophenotype of patients with kidney disease. We propose a definition of SIDKD and discuss the pathogenic mechanisms of SIDKD known thus far, including more recent insights into the unexpected immunoregulatory roles of elevated levels of FGF23 and hyperuricemia and shifts in the secretome of the intestinal microbiota in kidney disease. As an ultimate goal, we should aim to develop therapeutics that can reduce mortality due to infections in patients with kidney disease by normalizing host defense to pathogens and immune responses to vaccines.
  • |Adaptive Immunity[MESH]
  • |Blood Platelets/immunology[MESH]
  • |COVID-19 Vaccines/immunology[MESH]
  • |COVID-19/*etiology/immunology[MESH]
  • |Gastrointestinal Microbiome/immunology[MESH]
  • |Humans[MESH]
  • |Immunity, Innate[MESH]
  • |Immunologic Deficiency Syndromes/*etiology/immunology/prevention & control[MESH]
  • |Immunophenotyping[MESH]
  • |Models, Immunological[MESH]
  • |Pandemics[MESH]
  • |Renal Insufficiency, Chronic/*complications/immunology[MESH]
  • |Risk Factors[MESH]
  • |SARS-CoV-2[MESH]
  • |Seroconversion[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    259 2.33 2022